ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Idera’s TLR9-Yervoy combo sees ‘impressive’ disease control in PD-1-refractory melanoma
December 26, 2018After reporting positive phase 1 results suggesting its TLR9 agonist tilsotolimod could work in synergy with CTLA4 inhibitor Yervoy in melanoma patients who progress on anti-PD-1.... -
BioCryst terminates merger agreement with Idera
July 12, 2018US-based BioCryst Pharmaceuticals has terminated the merger agreement with Idera Pharmaceuticals after its stockholders voted against the proposed deal.
Pharma Sources Insight January 2025
